Trial Profile

A Phase 1 Clinical Study of NXP900 in Subjects with Advanced Cancers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NXP 900 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Nuvectis Pharma

Most Recent Events

31 Jul 2025 According to Nuvectis Pharma media release, the final data from the study is expected to be presented at a future medical/scientific conference.
31 Jul 2025 Status changed from recruiting to completed.
30 Apr 2025 Results (n=26) presented at the 116th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com